Volume 122, Issue 12 , Pages 1150.e1-1150.e9, December 2009
Comorbidities in Patients with Psoriasis
To access this article, please choose from the options below
Funding: Funding for writing assistance was provided by Amgen.
Conflict of Interest: Almost all of Dr Gottlieb's consulting and speaking fees are paid to Tufts Medical Center. Dr Gottlieb is a member of the speakers bureau of Amgen Inc, and Wyeth Pharmaceuticals; has current consulting/advisory board agreements with Amgen Inc, Centocor, Inc, Wyeth Pharmaceuticals, Celgene Corp, Bristol-Myers Squibb Co, Beiersdorf, Inc, Abbott, Roche, TEVA, Actelion, UCB, Novo Nordisk, Almirall, Immune Control, Dermipsor Ltd., Incyte, Magen Biosciences, Stieffel, and Puretech; Tufts Medical Center has received research/educational grants from Centocor, Inc, Amgen Inc, Wyeth Pharmaceuticals, Immune Control, Celgene Corp, Pharmacare, Incyte, Novo Nordisk, Pfizer, and Abbott. Dr Dann is a former Amgen employee. He has participated on speakers bureaus for Amgen Inc and Wyeth Pharmaceuticals and has a consulting agreement with Amgen.
Authorship: All authors had access to the data and played a role in writing this manuscript.
PII: S0002-9343(09)00684-6
doi:10.1016/j.amjmed.2009.06.021
© 2009 Elsevier Inc. All rights reserved.
Volume 122, Issue 12 , Pages 1150.e1-1150.e9, December 2009

